

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和鉑醫藥控股有限公司**  
**HBM Holdings Limited**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND  
CHANGES IN COMPOSITION OF BOARD COMMITTEES**

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that Mr. Ka Chi Yau (“**Mr. Yau**”) has tendered his resignation as an independent non-executive Director, the chairman of the audit committee of the Board (the “**Audit Committee**”) and a member of the remuneration committee of the Board (the “**Remuneration Committee**”) with effect from 21 June 2024 due to his desire to devote more time to his personal endeavors (the “**Resignation**”).

Mr. Yau has confirmed that he has no disagreement with the Board and that there is no other matter in respect of the Resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Mr. Yau for his valuable contribution to the Company during his tenure of office.

**CHANGES IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces that following the Resignation, with effect from 21 June 2024 (i) Dr. Xiaoping Ye, an independent non-executive Director, has been redesignated from a member to the chairman of the Audit Committee and redesignated from the chairman to a member of the Remuneration Committee, and (ii) Dr. Albert R. Collinson, an independent non-executive Director, has been appointed as a member of the Audit Committee and the chairman of the Remuneration Committee.

## **NON-COMPLIANCE WITH THE LISTING RULES**

Since Mr. Yau is the independent non-executive Director who has the appropriate professional qualifications or accounting or related financial management expertise (the “**Relevant Qualification**”) under Rule 3.10(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), following the Redesignation, there would be no independent non-executive Director who possesses the Relevant Qualification as required under Rule 3.10(2) of the Listing Rules; and the Audit Committee would comprise no independent non-executive Director with the Relevant Qualifications as required under Rule 3.21 of the Listing Rules. The Company is in the course of identifying suitable candidate(s) to act as an independent non-executive Director to meet the requirement set out in Rule 3.10(2) and 3.21 of the Listing Rules within three months from the date of the Resignation and will make further announcement as and when appropriate.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 21 June 2024

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Dr. Albert R. Collinson as independent non-executive Directors.*